We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

155 hedge funds and large institutions have $703M invested in Akebia Therapeutics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 54 increasing their positions, 42 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

676% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $1.4M

32% more capital invested

Capital invested by funds: $532M → $703M (+$171M)

29% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 42

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

1% more funds holding

Funds holding: 153 → 155 (+2)

0.62% more ownership

Funds ownership: 70.83% → 71.45% (+0.62%)

Holders
155
Holders Change
+2
Holders Change %
+1.31%
% of All Funds
3.42%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
27
Increased
54
Reduced
42
Closed
22
Calls
$10.9M
Puts
$1.4M
Net Calls
+$9.48M
Net Calls Change
+$6.58M

Top Buyers

1
CCM
Consonance Capital Management
New York
+$55.4M
2
FCM
Farallon Capital Management
California
+$9.72M
3
Invesco
Invesco
Georgia
+$8.83M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.45M

Top Sellers

1
BG
Baupost Group
Massachusetts
-$15.9M
2
Morgan Stanley
Morgan Stanley
New York
-$6.29M
3
Citadel Advisors
Citadel Advisors
Florida
-$5.36M
4
WP
Woodline Partners
California
-$5.03M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$133M -$15.9M -2,043,485 -10%
BlackRock
2
BlackRock
New York
$76.8M -$984K -126,528 -1%
CCM
3
Consonance Capital Management
New York
$54M +$55.4M +7,121,283 New
NCM
4
Nantahala Capital Management
Connecticut
$49.7M -$1.38M -177,642 -3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$44.6M +$2.84M +365,374 +7%
ACM
6
Abrams Capital Management
Massachusetts
$42.9M – – –
State Street
7
State Street
Massachusetts
$25.9M -$195K -25,066 -0.7%
NHAS
8
Novo Holdings A/S
Denmark
$25.7M +$2.28M +293,039 +9%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$15M -$2.99M -383,780 -16%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$14M +$2.23M +286,869 +18%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$13.8M +$1.3M +166,938 +10%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$13.1M +$6.45M +828,814 +92%
N
13
Nuveen
North Carolina
$11.3M -$1.88M -241,427 -14%
ClearBridge Investments
14
ClearBridge Investments
New York
$11.2M -$1.28M -164,645 -10%
Northern Trust
15
Northern Trust
Illinois
$11.1M -$32K -4,117 -0.3%
RHJA
16
Rice Hall James & Associates
California
$10.7M +$66.5K +8,543 +0.6%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$9.95M +$4.08M +524,334 +67%
FCM
18
Farallon Capital Management
California
$9.47M +$9.72M +1,250,000 New
Invesco
19
Invesco
Georgia
$8.61M +$8.83M +1,135,256 New
Fidelity Investments
20
Fidelity Investments
Massachusetts
$7.78M +$6.7M +861,808 +525%
Norges Bank
21
Norges Bank
Norway
$6.97M – – –
Millennium Management
22
Millennium Management
New York
$6.52M +$1.47M +189,157 +28%
DCM
23
DAFNA Capital Management
California
$6.47M +$646K +83,000 +11%
Goldman Sachs
24
Goldman Sachs
New York
$5.85M +$186K +23,866 +3%
Charles Schwab
25
Charles Schwab
California
$5.63M +$109K +13,991 +2%
1
2 3 4 5

AKBA Hedge Fund Activity: Q1 2020 in Review

155 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2020, worth a combined $703M — up 32% from $532M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AKBA positions and 22 closed out — a net gain of 5 holders — while 54 added to existing stakes and 42 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $55.4M. The largest seller was Baupost Group, cutting an estimated $15.9M.

  • 155 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2020, up from 153 in Q4 2019.
  • Funds reported $703M of Akebia Therapeutics stock for Q1 2020, up 32% quarter-over-quarter.
  • 27 funds opened new Akebia Therapeutics positions in Q1 2020 and 22 closed out, a net change of +5 holders.
  • The largest Akebia Therapeutics buyer in Q1 2020 was Consonance Capital Management, an estimated $55.4M added.
  • The largest Akebia Therapeutics seller in Q1 2020 was Baupost Group, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2020.